These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 33249427)

  • 1. FRMD6 has tumor suppressor functions in prostate cancer.
    Haldrup J; Strand SH; Cieza-Borrella C; Jakobsson ME; Riedel M; Norgaard M; Hedensted S; Dagnaes-Hansen F; Ulhoi BP; Eeles R; Borre M; Olsen JV; Thomsen M; Kote-Jarai Z; Sorensen KD
    Oncogene; 2021 Jan; 40(4):763-776. PubMed ID: 33249427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FRMD6 inhibits human glioblastoma growth and progression by negatively regulating activity of receptor tyrosine kinases.
    Xu Y; Wang K; Yu Q
    Oncotarget; 2016 Oct; 7(43):70080-70091. PubMed ID: 27661120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth.
    Blando J; Portis M; Benavides F; Alexander A; Mills G; Dave B; Conti CJ; Kim J; Walker CL
    Am J Pathol; 2009 May; 174(5):1869-79. PubMed ID: 19395652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.
    Song H; Zhang B; Watson MA; Humphrey PA; Lim H; Milbrandt J
    Oncogene; 2009 Sep; 28(37):3307-19. PubMed ID: 19597465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated expression of Par3 promotes prostate cancer metastasis by forming a Par3/aPKC/KIBRA complex and inactivating the hippo pathway.
    Zhou PJ; Xue W; Peng J; Wang Y; Wei L; Yang Z; Zhu HH; Fang YX; Gao WQ
    J Exp Clin Cancer Res; 2017 Oct; 36(1):139. PubMed ID: 29017577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision.
    Luchman HA; Benediktsson H; Villemaire ML; Peterson AC; Jirik FR
    PLoS One; 2008; 3(12):e3940. PubMed ID: 19081794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FERM domain-containing protein 6 exerts a tumor-inhibiting role in thyroid cancer by antagonizing oncogenic YAP1.
    Wang W; Zhao C; Quan F; Zhang P; Shao Y; Liu L
    Biofactors; 2022 Mar; 48(2):428-441. PubMed ID: 34669997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FERM domain-containing protein 6 identifies a subpopulation of varicose nerve fibers in different vertebrate species.
    Beck J; Kressel M
    Cell Tissue Res; 2020 Jul; 381(1):13-24. PubMed ID: 32200438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis.
    Ma X; Ziel-van der Made AC; Autar B; van der Korput HA; Vermeij M; van Duijn P; Cleutjens KB; de Krijger R; Krimpenfort P; Berns A; van der Kwast TH; Trapman J
    Cancer Res; 2005 Jul; 65(13):5730-9. PubMed ID: 15994948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CBP loss cooperates with PTEN haploinsufficiency to drive prostate cancer: implications for epigenetic therapy.
    Ding L; Chen S; Liu P; Pan Y; Zhong J; Regan KM; Wang L; Yu C; Rizzardi A; Cheng L; Zhang J; Schmechel SC; Cheville JC; Van Deursen J; Tindall DJ; Huang H
    Cancer Res; 2014 Apr; 74(7):2050-61. PubMed ID: 24491799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tumor suppressive effect of long non-coding RNA FRMD6-AS2 in uteri corpus endometrial carcinoma.
    Wang J; Li Z; Wang X; Ding Y; Li N
    Life Sci; 2020 Feb; 243():117254. PubMed ID: 31917993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel highly potent trivalent TGF-β receptor trap inhibits early-stage tumorigenesis and tumor cell invasion in murine Pten-deficient prostate glands.
    Qin T; Barron L; Xia L; Huang H; Villarreal MM; Zwaagstra J; Collins C; Yang J; Zwieb C; Kodali R; Hinck CS; Kim SK; Reddick RL; Shu C; O'Connor-McCourt MD; Hinck AP; Sun LZ
    Oncotarget; 2016 Dec; 7(52):86087-86102. PubMed ID: 27863384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-tissue FRMD6 expression predicts better outcomes among colorectal cancer patients.
    von Koskull A; Hagström J; Haglund C; Kaprio T; Böckelman C
    Biomarkers; 2024 May; 29(3):127-133. PubMed ID: 38385211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CircRNA VPRBP inhibits tumorigenicity of cervical cancer via miR-93-5p/FRMD6 axis.
    Shen L; Dang J; Liu S; Xian B; Deng Y; Qu D
    Reprod Sci; 2022 Aug; 29(8):2251-2264. PubMed ID: 35501594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sprouty genes function in suppression of prostate tumorigenesis.
    Schutzman JL; Martin GR
    Proc Natl Acad Sci U S A; 2012 Dec; 109(49):20023-8. PubMed ID: 23150596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human homolog of Drosophila expanded, hEx, functions as a putative tumor suppressor in human cancer cell lines independently of the Hippo pathway.
    Visser-Grieve S; Hao Y; Yang X
    Oncogene; 2012 Mar; 31(9):1189-95. PubMed ID: 21785462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MMAC/PTEN tumor suppressor gene regulates vascular endothelial growth factor-mediated angiogenesis in prostate cancer.
    Koul D; Shen R; Garyali A; Ke LD; Liu TJ; Yung WK
    Int J Oncol; 2002 Sep; 21(3):469-75. PubMed ID: 12168088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic silencing of MEIS2 in prostate cancer recurrence.
    Nørgaard M; Haldrup C; Bjerre MT; Høyer S; Ulhøi B; Borre M; Sørensen KD
    Clin Epigenetics; 2019 Oct; 11(1):147. PubMed ID: 31640805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Willin/FRMD6 expression activates the Hippo signaling pathway kinases in mammals and antagonizes oncogenic YAP.
    Angus L; Moleirinho S; Herron L; Sinha A; Zhang X; Niestrata M; Dholakia K; Prystowsky MB; Harvey KF; Reynolds PA; Gunn-Moore FJ
    Oncogene; 2012 Jan; 31(2):238-50. PubMed ID: 21666719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MPDZ as a novel epigenetic silenced tumor suppressor inhibits growth and progression of lung cancer through the Hippo-YAP pathway.
    Liu W; Huang Y; Wang D; Han F; Chen H; Chen J; Jiang X; Cao J; Liu J
    Oncogene; 2021 Jul; 40(26):4468-4485. PubMed ID: 34108620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.